FAST-Trac Award
FAST-Trac Award supports researchers working on translational research, therapeutic development, and clinical-trial readiness to accelerate potential treatments for Angelman syndrome.
Browse similar grants
Funder: Foundation for Angelman Syndrome Therapeutics (FAST)
Due Dates: Rolling (LOIs and applications; no fixed deadline)
Funding Amounts: Maximum recommended $150,000 per year for one or two years, allocated annually; larger requests considered exceptionally
Summary: Supports translational research, therapeutic development, and clinical-trial readiness to advance potential treatments for Angelman syndrome.
Key Information: A Letter of Intent is required before applying; applicants need training and experience at least equivalent to PhD or MD level.
Description
FAST Targeted Research to Advance a Cure (FAST-TRAC) supports translational research that accelerates potential treatments for Angelman syndrome. Run by the Foundation for Angelman Syndrome Therapeutics, the program emphasizes gene-modifying, disease-modifying, and symptom-alleviating therapeutics. It also funds high-throughput drug-screening platforms and tools, alongside innovative in vitro and in vivo disease models for discovering and assessing novel therapeutics.
The award also supports preparation for clinical trials, including Angelman-specific biomarkers and outcome measures, clinical-site preparation, comprehensive natural history data, and new information needed to advance prospective treatments. Funded research is expected to generate data useful for future grants and publications.
